Y-mAbs Therapeutics (YMAB) Scheduled to Post Quarterly Earnings on Friday

Y-mAbs Therapeutics (NASDAQ:YMAB) is scheduled to issue its quarterly earnings data before the market opens on Friday, November 8th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter. Y-mAbs Therapeutics has set its FY 2024 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The company had revenue of $22.80 million during the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the prior year, the company earned ($0.14) EPS. On average, analysts expect Y-mAbs Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $14.51 on Friday. Y-mAbs Therapeutics has a 1 year low of $4.69 and a 1 year high of $20.90. The company has a market capitalization of $646.71 million, a PE ratio of -30.33 and a beta of 0.70. The company has a fifty day moving average of $14.01 and a two-hundred day moving average of $13.16.

Insider Activity

In related news, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, insider Thomas Gad sold 65,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $13.47, for a total transaction of $875,550.00. Following the completion of the transaction, the insider now directly owns 97,681 shares in the company, valued at $1,315,763.07. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the transaction, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 100,000 shares of company stock worth $1,338,100. Company insiders own 21.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. BMO Capital Markets decreased their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday, August 13th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $21.14.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.